Delvens published a new research publication on "In-Vitro Diagnostics Market Insights, to 2030" with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the In-Vitro Diagnostics market was mainly driven by the increasing RD spending across the world.
The global In-Vitro Diagnostics market size was estimated at USD 120.7 billion in 2023 and is projected to reach USD 161.2 billion in 2030 at a CAGR of 4.2% during the forecast period 2023-2030.
Get Free Sample Report: https://www.delvens.com/get-free-sample/in-vitro-diagnostics-market
In May 2021, the esteemed University of California accomplished a remarkable feat in the field of medical science by developing a highly sensitive molecular test. This particular test capitalizes on cutting-edge chip technology and is capable of detecting the presence of both influenza A and SARS-CoV-2 antigens.
The industry dynamics have witnessed a significant shift, with an ever-growing number of players directing their focus towards the development and launch of tests for at-home use. Furthermore, in the year 2021, the Food and Drug Administration (FDA) has demonstrated an increased proclivity towards prioritizing home-based molecular diagnostic tests.
Regional Analysis
North America to Dominate the Market
- The market dominance of the United States in the North American region can be attributed to the escalation of healthcare expenditure and the expeditious implementation of point-of-care testing. This notion is supported by the Centers for Disease Control and Prevention, which has provided data on chronic diseases.
- According to the American Cancer Society, in January 2022, cancer continues to be the second most common cause of death in the United States
Competitive Landscape
- Abbott
- bioMérieux SA
- Quidel Corp.
- Siemens Healthineers
- Bio-Rad Laboratories, Inc.
- Qiagen
- Sysmex Corp.
- Charles River Laboratories
- Quest Diagnostics
- Agilent Technologies, Inc.
- Danaher Corporation
- Becton Dickinson and Company
- Hoffmann-La Roche Ltd. and More
For More Inquiry Contact us: https://www.delvens.com/Inquire-before-buying/in-vitro-diagnostics-market
Recent Developments
- In November 2022, Thermo Fisher Scientific, launched the rapid RT-PCR Accula Flu A/Flu B Test Designed to enable healthcare providers to detect and differentiate influenza A and B in about 30 minutes.
- In October 2022, Thermo Fisher Scientific entered a definitive areement to acquire the biding site group a global leader in specially diagnostics.
The In-Vitro Diagnostics Market is segmented into various segments such as Product And Services, Technique, Application, End-User, and region:
Based on Product and Services:
- Reagents
- Instruments
- Software and Services
Based on the Technique:
- Immunodiagnostics
- Hematology
- Molecular Diagnostics
- Tissue Diagnostics
- Clinical Chemistry
Based on the Application
- Infectious Diseases
- Cancer
- Cardiac Diseases
- Immune System Disorders
- Nephrological Diseases
- Gastrointestinal Diseases
Based on End-User
- Standalone laboratories
- Hospitals
- Academic and Medical Schools
- Point of Care
Access Full Report: https://www.delvens.com/report/in-vitro-diagnostics-market
In addition to the market data for the In-Vitro Diagnostics Market, Delvens offers client-centric reports customized according to the company’s specific demand and requirements.
More Reports From Delvens:
Magnetic Resonance Imaging (MRI) Coils market size was estimated at USD 8.81 billion in 2023 and is projected to reach USD 15.7 billion in 2030 at a CAGR of 7.5% during the forecast period 2023-2030.
Endoscopic Retrograde Cholangiopancreatography (ERCP) and Percutaneous Transhepatic Cholangiography (PTC) Devices market size was estimated at USD 1.8 billion in 2023 and is projected to reach USD 2.7 billion in 2030 at a CAGR of 6.2% during the forecast period 2023-2030.
Diagnostic Imaging Services market size was estimated at USD 610 billion in 2023 and is projected to reach USD 872.7 billion in 2030 at a CAGR of 5.25% during the forecast period 2023-2030.
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT Telecom, Chemicals Materials, Semiconductor Electronics, Energy, Pharmaceutical, Consumer Goods Services, Food Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-3290-6466
+1 214-377-1144
